Omar Aref, MD
Family Medicine · Plant City, FLNPI 1235106675
Payments from drug & device makers
Across 361 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Lilly USA, LLC$1K
- AbbVie$782
- Novo Nordisk$776
- Lucid Diagnostics Inc.$258
- GSK$256
- plus $2K from 30 others
What the payments were for
- Food & beverage$6,75699%
- Education$351%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 59 | $1,487 |
| Lilly USA, LLC | 71 | $1,172 |
| AbbVie(2 entities) | 49 | $782 |
| Novo Nordisk | 42 | $776 |
| Lucid Diagnostics Inc. | 19 | $258 |
| GSK | 14 | $256 |
| Bayer | 9 | $228 |
| Sanofi-aventis U.S. LLC | 12 | $225 |
| Amgen | 14 | $214 |
| Exact Sciences | 8 | $162 |
| Pfizer | 9 | $158 |
| Novartis | 6 | $122 |
| Johnson & Johnson | 6 | $109 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $105 |
| Boehringer Ingelheim | 4 | $89 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $85 |
| Mannkind Corporation | 1 | $59 |
| Merck | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
| Dexcom, Inc. | 2 | $46 |
| Eisai Inc. | 2 | $44 |
| Inari Medical, Inc. | 2 | $44 |
| Abbott | 3 | $40 |
| Idorsia Pharmaceuticals US Inc | 2 | $39 |
| Biohaven Pharmaceuticals, Inc. | 2 | $38 |
| Axsome Therapeutics, Inc. | 1 | $33 |
| Pharming Healthcare, Inc. | 2 | $30 |
| Si-bone, Inc. | 1 | $24 |
| Shire North American Group Inc | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Shield Therapeutics Inc | 1 | $16 |
| Corcept Therapeutics | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| QOL Medical, LLC | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,851 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 42 | $59,588 |
| EliquisApixaban | 27 | $34,883 |
| MounjaroTirzepatide | 18 | $31,470 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $27,242 |
| JardianceEmpagliflozin | 25 | $20,778 |
| FarxigaDapagliflozin Propanediol | 13 | $19,067 |
| Xigduo XrDapaglifloz Propaned/Metformin | 16 | $17,190 |
| VascepaIcosapent Ethyl | 15 | $7,216 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 31 | $2,928 |
| Atorvastatin Calcium | 211 | $2,872 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $2,771 |
| Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid | 14 | $2,320 |
| Rosuvastatin Calcium | 80 | $2,094 |
| Levocetirizine Dihydrochloride | 64 | $1,818 |
| Levothyroxine Sodium | 127 | $1,468 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $776 | $59,58842 claims |
| PfizerEliquis | $158 | $34,88327 claims |
| Lilly USA, LLCMounjaro | $1,172 | $31,47018 claims |
| Boehringer IngelheimJardiance | $89 | $20,77825 claims |
| AstraZenecaFarxiga | $1,487 | $19,06713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Plant City
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.